UpHealth, Inc. Announces NUTRAscriptives™ Direct, Expedited Delivery For Clinical-Grade Nutritional Supplements
UpHealth, Inc. (NYSE: UPH) has announced the launch of NUTRAscriptives™ Direct, expanding its clinical-grade supplement line. This service enables healthcare providers to offer high-quality nutritional supplements directly to patients via an app, requiring no inventory investment. With expedited shipping, it supports providers in generating additional revenue with a proven ROI. Currently in beta testing, the service will launch in Q1 2022 across the U.S. and Puerto Rico. UpHealth aims to enhance patient care through its digital health solutions and commitment to regulatory compliance.
- Launch of NUTRAscriptives™ Direct service providing clinical-grade supplements.
- No overhead costs for providers with expedited direct shipping to patients.
- Supports revenue generation for providers with a proven ROI.
- Currently in beta testing, expected to launch in Q1 2022.
- None.
DELRAY BEACH, Fla., Oct. 13, 2021 /PRNewswire/ -- UpHealth, Inc. (NYSE: UPH) announced an expansion of its NUTRAscriptives™ product line of clinical-grade supplements distributed online, in retail stores and directly by providers. NUTRAscriptives™ Direct offers providers an easy-to-support business model to offer patients high quality supplements to augment their care plans. The new service further extends UpHealth leadership in the management of health with personalized protocols.
NUTRAscriptives™ Direct provides high quality nutritional supplements available to providers with an easy to administer business model that enables patients to access provider-recommended supplements through any browser or a downloadable app to place orders. NUTRAscriptives™ Direct drop ships the order for expedited shipping directly to patients and their families.
The NUTRAscriptives™ Direct service addresses a need of providers to offer clinical-grade nutritional supplements with no overhead or investment in inventory. The new option supports additional revenue source for providers with a proven return on investment (ROI) and gives providers the flexibility to choose which supplements they offer and adjust the price to support their unique market needs.
"Our patients deserve the highest quality, potency and safety available," said Dr. Guy Domm, of Armur Medical, an innovative provider group working to improve health with an integrative approach. "Clinically, I trust NUTRAscriptives™ as evidenced on lab values for my patients," Dr. Domm added, "I know these products are independently third-party tested for integrity. My patients are getting the quality they deserve."
"NUTRAscriptives™ Direct responds to our customers' need to provide high-quality clinical-grade supplements with an unwavering commitment to regulatory compliance, exceptional customer service, and national distribution capabilities. NUTRAscriptives™ Direct simplifies the ability for providers to offer our existing line of nutritional supplements with a business model that assures a solid ROI with virtually no overhead." said Mike Rolla, Chief Revenue Officer of UpHealth, Inc.
The new service and web/mobile application are currently in beta testing with providers. NUTRAscriptives™ Direct will be rolled out to the provider community in the U.S. and Puerto Rico in Q1 2022.
About UpHealth, Inc.
UpHealth is a global digital health company that delivers digital-first technology, infrastructure and services to dramatically improve how healthcare is delivered and managed. The UpHealth platform creates digitally enabled "care communities" that improve access and achieve better patient outcomes at lower cost, through digital health solutions and interoperability tools that serve patients wherever they are, in their native language. UpHealth's clients include global governments, health plans, healthcare providers and community-based organizations.
For more information, please visit https://uphealthinc.com and follow us at @UpHealthInc on Twitter and UpHealth Inc on Linkedin.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the availability of the NUTRAscriptives™ Direct product line in Q1 2022, and the plans, prospects or strategies regarding this product line. Any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on our management team's current expectations and beliefs. There can be no assurance that future developments affecting UpHealth will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including regulatory approvals, the ability to manufacture and deliver products as expected and the demand for such products. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Additional factors that could cause actual results to differ are discussed under the heading "Risk Factors" and in other sections of UpHealth's filings with the SEC, and in UpHealth's current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to UpHealth as of the date hereof, and UpHealth assumes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
View original content to download multimedia:https://www.prnewswire.com/news-releases/uphealth-inc-announces-nutrascriptives-direct-expedited-delivery-for-clinical-grade-nutritional-supplements-301399100.html
SOURCE UpHealth, Inc.
FAQ
What is NUTRAscriptives™ Direct by UpHealth?
When will NUTRAscriptives™ Direct be available?
How does NUTRAscriptives™ Direct benefit healthcare providers?
What is UpHealth's approach to supplement safety?
